243 related articles for article (PubMed ID: 34816130)
1. Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis.
Sun HY; Keller E; Suresh H; Sebaratnam DF
JAAD Int; 2021 Dec; 5():1-8. PubMed ID: 34816130
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective.
Zhang J; Xia Z; Guo W; Ren X; Liu F; Ratnaparkhi G; Pagada A; Subramanian S; Hu M; Chen W
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2681-2696. PubMed ID: 37741954
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn AM; Lowry S; Feldman S; Wu JJ; Armstrong AW
J Dermatolog Treat; 2022 Mar; 33(2):740-748. PubMed ID: 32602762
[TBL] [Abstract][Full Text] [Related]
4. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan.
Saeki H; Ishii K; Joshi A; Bensimon AG; Yang H; Kawaguchi I
J Dermatolog Treat; 2022 Feb; 33(1):229-239. PubMed ID: 32178555
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
6. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
9. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
[No Abstract] [Full Text] [Related]
10. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
Nyholm N; Schnack H; Danø A; Skowron F
Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
12. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Warren RB; See K; Burge R; Zhang Y; Brnabic A; Gallo G; Garrelts A; Egeberg A
Dermatol Ther (Heidelb); 2020 Feb; 10(1):73-86. PubMed ID: 31686337
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
[TBL] [Abstract][Full Text] [Related]
17. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
